ALS Therapy Radicava Seen to Uphold Benefits Over Nearly a Year in Extension Trial, Says MT Pharma
Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the treatment continued to provide benefits after 48 weeks of treatment. These findings — presented by researchers from MT Pharma America at the May 18-20 European Network for the Cure…